Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of early pregnancy location and viability compared with hCG, progesterone and estradiol.

Autor: Friis Petersen J; Department of Obstetrics and Gynecology, North Zealand Hospital, Dyrehavevej 29, 3400 Hillerød, Denmark. Electronic address: jesper.friis.petersen@regionh.dk., Grynnerup AG; Department of Obstetrics and Gynecology, The Fertility Clinic, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, 2650 Hvidovre, Denmark., Mitchell NH; Department of Clinical Biochemistry, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, 2650 Hvidovre, Denmark., Løssl K; The Fertility Clinic 4071, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark., Sørensen S; Clinical Research Centre, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, 2650 Hvidovre, Denmark., Lindhard A; Department of Obstetrics and Gynecology, Zealand University Hospital Roskilde, Sygehusvej 10, 4000 Roskilde, Denmark., Friis-Hansen L; Department of Clinical Biochemistry, North Zealand Hospital, Dyrehavevej 29, 3400 Hillerød, Denmark., Pinborg A; Department of Obstetrics and Gynecology, The Fertility Clinic, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, 2650 Hvidovre, Denmark; The Fertility Clinic 4071, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark., Nyboe Andersen A; The Fertility Clinic 4071, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark., Løkkegaard E; Department of Obstetrics and Gynecology, North Zealand Hospital, Dyrehavevej 29, 3400 Hillerød, Denmark.
Jazyk: angličtina
Zdroj: Journal of reproductive immunology [J Reprod Immunol] 2020 Apr; Vol. 138, pp. 103103. Date of Electronic Publication: 2020 Feb 15.
DOI: 10.1016/j.jri.2020.103103
Abstrakt: A circulating biomarker of early pregnancy outcome independent of ultrasonography and gestational age is a coveted goal. This study evaluated soluble urokinase plasminogen activator receptor (suPAR), a well-described marker of inflammation and immunological activation, for this purpose, and compared it with established early pregnancy biomarkers of the luteoplacental phase: progesterone, estradiol and hCG. We merged data from two prospective first trimester cohorts to conduct a case-control study comparing these analytes in women who had either a live birth, a miscarriage or an ectopic pregnancy. The ability to predict pregnancy location and viability was assessed by areas under the receiver operating characteristic curves (AUC). Comparing women irrespective of gestational age with a live birth, miscarriage or ectopic pregnancy showed significantly lower suPAR values in the latter group (2.4 vs. 2.4 vs. 2.0 μg/L, p = 0.032, respectively), as were all other analytes. Before 6 weeks' gestation, suPAR was significantly inferior to progesterone, estradiol and hCG in pregnancy location and viability prediction (in 124 pregnancies, suPAR AUC location = 0.69 [CI: 0.54-0.83] and AUC viability = 0.58 [CI: 0.48-0.69], while progesterone AUC location = 0.95 [CI: 0.87-1.00] and AUC viability = 0.84 [CI: 0.75-0.92]). After 6 weeks' gestation, suPAR prediction improved but was inferior to hCG, progesterone and estradiol (in 188 pregnanices, suPAR AUC location = 0.71 [CI: 0.63-0.78] and AUC viability = 0.70 [CI: 0.63-0.78] compared with hCG AUC location = 0.96 [CI: 0.93-0.99] and AUC viability = 0.96 [CI: 0.93-0.98]). Collectively, suPAR is less useful as a predictor of early pregnancy outcome than hCG, progesterone and estradol.
Competing Interests: Declaration of Competing Interest Outside the submitted work Anders Nyboe Andersen reports grants and personal fees from Ferring, MSD and Gedeon-Richter and personal fees and honoraria from Merck Serono, MSD, Novo-Nordisk and Abbott. All other authors declare no conflict of interest.
(Copyright © 2020 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: